AMGN vs MRNA vs ROIV Stock Comparison

Amgen, Moderna and Roivant Sciences Prices as of Nov 13, 2026 Peers: Industry group
AMGN Amgen Inc
$465.67 +9.3% 1M +38.6% 1Y
Market cap
$250.23B
P/E
26.6x
Revenue (TTM)
$38.90B
Div. yield
0.02%
Biotechnology Healthcare
4 wins
MRNA Moderna, Inc.
$223.37 -1.3% 1M +794.9% 1Y
Market cap
$86.12B
P/E
–
Revenue (TTM)
$2.53B
Div. yield
–
Biotechnology Healthcare
2 wins
ROIV Roivant Sciences Ltd.
$39.53 +17.6% 1M +92.3% 1Y
Market cap
$27.84B
P/E
–
Revenue (TTM)
$41.08M
Div. yield
–
Biotechnology Healthcare
3 wins

Head to Head

9 decided of 12

Amgen leads on 4 of the 12 questions below (Amgen 4, Roivant Sciences 3, Moderna 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMGNMRNAROIVLeader
Larger companyMarket capitalisation $250.23B $86.12B $27.84B AMGN
Cheaper on earningsLower P/E, profitable companies only 26.6x -30.9x -80.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 20.9x — — –
Faster revenue growthRevenue growth, trailing twelve months +8.2% +13.1% +102.1% ROIV
More profitableNet margin, trailing twelve months 24.1% -110.5% -838.2% AMGN
Better return on capitalReturn on invested capital 15.6% -39.6% — AMGN
Less leveragedLower net debt / EBITDA 2.4x 1.7x — MRNA
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +38.6% +794.9% +92.3% MRNA
Better 5-year returnAnnualised price return, 5 years +17.1%/yr -0.7%/yr +36.3%/yr ROIV
Less volatileAnnualised volatility, 1 year 28.8% 130.6% 46.2% AMGN
Higher overall scoreMean of the five percentile scores vs peers 66/100 60/100 78/100 ROIV

Percentile Scorecard

AMGNMRNAROIV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMGNMRNAROIV
Valuation 85 #103 of 660 69 #208 of 660 69 #207 of 660
Growth 61 #245 of 619 45 #344 of 619 86 #88 of 619
Profitability 95 #32 of 595 60 #239 of 595 51 #294 of 595
Financial Health 23 #528 of 683 52 #330 of 683 93 #47 of 683
Shareholder Returns 67 #152 of 459 76 #112 of 459 92 #40 of 459
Overall 66 60 78
  • AMGN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • MRNA ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ROIV ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMGNMRNAROIVSPY
1 month +9.3%-1.3%+17.6% -2.0%
3 months +12.2%+252.8%+9.2% -2.8%
6 months +42.7%+355.5%+35.0% +2.0%
Year to date +42.3%+657.4%+82.2% +10.6%
1 year +38.6%+794.9%+92.3% +12.2%
3 years +72.5%+201.4%+325.1% +68.1%
3 years, per year +19.9%+44.5%+62.0% +18.9%
5 years +120.3%-3.4%+370.6% +61.4%
5 years, per year +17.1%-0.7%+36.3% +10.1%
10 years +212.4%—— +248.5%
10 years, per year +12.1%—— +13.3%

Risk

MeasureAMGNMRNAROIVSPY
Volatility, 1Y 28.8%130.6%46.2% 13.6%
Downside volatility, 1Y 28.4%79.2%33.3% 13.9%
Beta vs S&P 500, 1Y 0.492.261.10 1.00
Return / volatility, 1Y 1.346.092.00 0.90
Max drawdown, 5Y -26.7%-93.9%-79.2% -25.4%
From 52-week high -2.7%-16.9%-5.5% -3.2%
52-week high $478.48$268.86$41.85 $779.14
52-week low $313.85$22.36$20.10 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMGNMRNAROIV
P/E now vs peer median 26.8xmedian 17.0x -32.1xmedian 17.0x -83.0xmedian 17.0x
P/S now vs peer median 6.5xmedian 8.4x 35.7xmedian 8.4x 696.3xmedian 8.4x
EV/EBITDA now vs peer median 17.1xmedian 14.6x -32.0xmedian 14.6x -43.9xmedian 14.6x
P/FCF now vs peer median 26.3xmedian 19.0x -45.8xmedian 19.0x -858.0xmedian 19.0x
P/B now vs peer median 17.6xmedian 2.0x 13.2xmedian 2.0x 6.2xmedian 2.0x
PEG now vs peer median 3.86median 0.43 -3.01median 0.43 -2.97median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMGNMRNAROIV
Revenue $38.90B $2.53B $41.08M
Gross profit $27.58B $707.00M $36.43M
Operating income $12.61B -$2.93B -$557.96M
Net income $9.39B -$2.79B -$440.18M
Free cash flow $9.58B -$1.97B -$33.34M
R&D $7.84B $2.66B $712.09M
EPS (diluted) $17.20 $-6.49 $-0.48
Cash & equivalents $13.19B $1.20B $1.64B
Total debt $54.01B $591.00M –
Shares (diluted) 546.00M 430.00M 722.75M
Enterprise value $201.89B $64.81B $10.97B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMGNMRNAROIV
P/E 26.8x -32.1x -83.0x
P/FCF 26.3x -45.8x -858.0x
P/Operating cash flow 20.9x -50.6x -786.2x
P/S 6.5x 35.7x 696.3x
P/B 17.6x 13.2x 6.2x
P/Tangible book -48.6x 13.2x 6.2x
EV/EBITDA 17.1x -32.0x -43.9x
EV/EBIT 23.2x -29.2x -43.7x
EV/Revenue 7.5x 33.9x 593.9x
EV/FCF 30.5x -43.5x -731.8x
EV/Operating cash flow 24.3x -48.0x -670.5x
PEG (3Y EPS CAGR) 3.86 -3.01 -2.97

Growth

14 metrics
MetricAMGNMRNAROIV
Revenue growth (1Y) 8.2% 13.1% 102.1%
Revenue CAGR (3Y) 13.2% -34.8% 0.9%
Gross profit growth (1Y) 15.9% -34.4% 85.9%
Gross profit CAGR (3Y) 11.8% -41.0% -1.3%
Operating income growth (1Y) 45.4% 15.4% 51.5%
Operating income CAGR (3Y) 12.5% -3.2% 12.5%
Net income growth (1Y) 34.1% 10.5% 15.8%
Net income CAGR (3Y) 7.5% 7.0% 25.4%
EPS growth (1Y) 33.1% 18.8% 13.2%
EPS CAGR (3Y) 6.9% 10.7% 28.0%
Operating cash flow growth (1Y) -8.3% 9.8% 95.3%
Operating cash flow CAGR (3Y) 4.4% 4.9% 65.0%
Free cash flow growth (1Y) -17.0% 25.7% 95.7%
Free cash flow CAGR (3Y) 0.7% 9.5% 66.0%

Profitability

14 metrics
MetricAMGNMRNAROIV
Gross margin 70.9% 28.0% 88.7%
EBITDA margin 43.9% -105.9% -1,352%
Operating margin 32.4% -116.0% -1,358%
Pretax margin 28.4% -108.1% -723.4%
Net margin 24.1% -110.5% -838.2%
FCF margin 24.6% -78.0% -81.2%
Operating cash flow margin 30.9% -70.7% -88.6%
Return on equity 72.1% -41.0% -8.1%
Return on assets 9.8% -22.8% -7.5%
Return on invested capital 15.6% -39.6% –
Return on capital employed 17.4% -28.8% -11.5%
Asset turnover 0.4x 0.2x 0.0x
Cash conversion (OCF / net income) 1.3x 0.6x 0.1x
Stock comp / revenue 1.3% 18.4% 819.9%

Financial Health

11 metrics
MetricAMGNMRNAROIV
Debt / assets 56.2% 4.4% –
Debt / equity 3.8x 0.1x –
Net debt / EBITDA 2.4x 1.7x –
Debt / FCF 5.6x -0.3x –
Liabilities / assets 85.1% 49.2% 7.6%
Equity / assets 14.9% 50.8% 92.4%
Interest coverage 4.8x – –
Current ratio 1.5x 3.6x 15.6x
Quick ratio 1.0x 3.2x 15.0x
Cash ratio 0.6x 2.5x 15.0x
Altman Z-score 2.54 8.66 45.44

Shareholder Returns

7 metrics
MetricAMGNMRNAROIV
Dividend yield 2.1% – –
Net buyback yield – -0.2% 0.4%
Shareholder yield 2.1% -0.2% 0.4%
Payout ratio (earnings) 57.1% – –
Payout ratio (FCF) 56.0% – –
Dividend growth (1Y) 6.3% – –
Dividend CAGR (3Y) 6.4% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMGNMRNAROIV
Forward P/E 20.9xFY2026 – –
EPS, next fiscal year $22.28FY2026 $-7.17FY2026 $-1.22FY2026
EPS growth, next FY +2.0%FY2026 – –
EPS growth, the year after +7.2% – –
Revenue, next fiscal year $42.01BFY2026 $2.22BFY2026 $158.10MFY2026
Revenue growth, next FY +14.3%FY2026 +14.6%FY2026 +1,814.0%FY2026
Revenue growth, the year after +3.1% +25.8% +317.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMGNMRNAROIV
Held by institutions 82.7% 80.2% 77.0%
Institutions holding 3,163 787 500
Change in shares held, QoQ +4.5% +3.4% +5.1%
Institutions buying 1,452 404 304
Institutions selling 1,219 239 138
Buyers to sellers 1.19 1.69 2.20

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMGNMRNAROIV
AMGN 1.00 0.27 0.10
MRNA 0.27 1.00 0.18
ROIV 0.10 0.18 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMGN, MRNA and ROIV?

Amgen (AMGN) is the largest by market capitalisation: Amgen (AMGN) $250.23B, Moderna (MRNA) $86.12B, Roivant Sciences (ROIV) $27.84B.

Which company is growing faster?

Roivant Sciences (ROIV) grew revenue fastest over the trailing twelve months: Amgen (AMGN) +8.2%, Moderna (MRNA) +13.1%, Roivant Sciences (ROIV) +102.1%.

Which company is more profitable?

Amgen (AMGN) has the highest net margin (Amgen (AMGN) 24.1%, Moderna (MRNA) -110.5%, Roivant Sciences (ROIV) -838.2%). On return on invested capital, Amgen (AMGN) leads (Amgen (AMGN) 15.6%, Moderna (MRNA) -39.6%).

Which stock has performed better?

Over the past year Moderna (MRNA) returned the most: Amgen (AMGN) +38.6%, Moderna (MRNA) +794.9%, Roivant Sciences (ROIV) +92.3%. Over five years, Roivant Sciences (ROIV) compounded fastest (Amgen (AMGN) +17.1%/yr, Moderna (MRNA) -0.7%/yr, Roivant Sciences (ROIV) +36.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Amgen (AMGN) 0.02%, Moderna (MRNA) 0.00%, Roivant Sciences (ROIV) 0.00%. Moderna (MRNA) and Roivant Sciences (ROIV) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Amgen (AMGN) has been the steadiest (Amgen (AMGN) 28.8%, Moderna (MRNA) 130.6%, Roivant Sciences (ROIV) 46.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AMGN, MRNA and ROIV?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Amgen (AMGN) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.